Generic Drugs Hit Backlog At FDA
No Plans to Expand Review CapabilitiesBy Marc Kaufman
Washington Post Staff Writer
Saturday, February 4, 2006; Page A01
At a time when low-cost generic drugs are being embraced as among the few ways to slow skyrocketing health care costs, the Food and Drug Administration has a backlog of more than 800 applications to bring new generic products to the market -- an all-time high.
As a result, experts say, fewer generic drugs will be available to consumers in the years ahead than the industry is ready and able to provide. The FDA, however, has told Congress that the office that reviews new generics needs no additional money, and the agency has no plans to hire more reviewers."We are very aware that many, many people are waiting for more generics to be approved and that there is frustration about the backlog," said Gary Buehler, director of the agency's Office of Generic Drugs.
He said he expects a record number of applications this year -- and an even larger backlog -- because "we don't believe we'll be getting any staff increases in 2006." Buehler said his office received an all-time monthly high of 129 applications in December.
http://www.washingtonpost.com/wp-dyn/content/article/2006/02/03/AR2006020302598.htmlBushCo continues to pay back the Drug Co's for their contributions.
Thanks for the checks, we'll make sure the generics come on line slooooowwwwly.